Publications by authors named "S Kasimir-Bauer"
Background: Leucine-rich α-2 glycoprotein 1 (LRG-1) is a secreted glycoprotein that is mainly produced in the liver. Elevated levels of LRG-1 are found in a multitude of pathological conditions including eye diseases, diabetes, infections, autoimmune diseases, and cancer. In patients with early breast cancer (BC), high intratumoral LRG-1 protein expression levels are associated with reduced survival.
View Article and Find Full Text PDFBiomarkers to identify metastatic breast cancer (mBC) patients resistant to CDK4/6 inhibition (CDK4/6i) are currently missing. We evaluated the usefulness of the monocyte-to-lymphocyte ratio (MLR), the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) as predictive markers for de novo resistance to CDK4/6i. Various blood cell counts and MLR, NLR, PLR were recorded before treatment initiation (baseline) and four weeks later from 97 mBC patients receiving endocrine therapy (ET) alone or in combination with CDK4/6i.
View Article and Find Full Text PDFThe Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management.
Cancers (Basel)
November 2023
Article Synopsis
- Analyzing blood components like circulating tumor cells and cell-free DNA in breast cancer patients has the potential to improve therapy management and make clinical decisions more personalized.
- Although advancements in multi-cancer early detection tests are notable, they aren't yet part of standard clinical practices.
- While specific biomarkers from blood analyses show strong prognostic value, their practical application in clinical management remains debated, highlighting the need for further research and standardization.
Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients.
Front Immunol
June 2023
Article Synopsis
- Triple negative breast cancer (TNBC) is aggressive and has few treatment options, highlighting the need for markers to identify high-risk patients and potential new therapies.
- Researchers studied sHLA-G plasma levels and ILT-2 gene variations in TNBC patients and healthy controls to assess their correlation with disease outcomes and circulating tumor cell (CTC) subtypes.
- Elevated post-chemotherapy sHLA-G levels were linked to worse outcomes, while the ILT-2 genetic variant was associated with poor disease progression, suggesting that combining these factors could better predict TNBC prognosis than traditional methods.
Purpose: Evaluate the diagnostic potential of [F]FDG-PET/MRI data compared with invasive acquired biomarkers in newly diagnosed early breast cancer (BC).
Methods: Altogether 169 women with newly diagnosed BC were included. All underwent a breast- and whole-body [F]FDG-PET/MRI for initial staging.